Seer, Inc. (Nasdaq: SEER) has announced a groundbreaking achievement in cancer research with PrognomiQ’s completion of the largest and most comprehensive unbiased mass spectrometry plasma biomarker study to date. The study, which utilized the Seer Proteograph™ Product Suite and Thermo Fisher Scientific’s Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, has achieved unprecedented scale and depth in early cancer detection research.
The study involved a multi-cancer case-control cohort of 2,840 subjects and successfully detected over 13,000 protein groups in plasma, with an average of over 8,200 protein groups per sample. PrognomiQ collected blood samples across 77 clinical sites in the U.S. and processed plasma samples using their in-house Seer Proteograph SP100 instruments and XT assays. The resulting peptides were sent to the Seer Technology Access Center (STAC) in Redwood City to be analyzed using the Orbitrap Astral mass spectrometers.
Dr. Bruce Wilcox, Chief Technology Officer of PrognomiQ, emphasized the significance of this study in cancer biomarker research, stating that the depth and breadth of data obtained have the potential to revolutionize early cancer detection.
The complete study results will be presented by Dr. Wilcox in an oral presentation at the American Society of Mass Spectrometry (ASMS) Conference, allowing the wider scientific community to explore the groundbreaking findings. This study has been made possible through the collaboration and partnership between Seer and Thermo Fisher, resulting in an unprecedented level of depth and sensitivity in proteomics research.
John Lesica, President of Chromatography and Mass Spectrometry at Thermo Fisher, expressed excitement at the impact of the Orbitrap Astral on unbiased biomarker discovery in such a comprehensive study. The collaboration with Seer to launch the STAC signifies their commitment to advancing proteomics research and its application in healthcare.
Omid Farokhzad, CEO and Chair of Seer, highlighted the significance of the study as the largest and most comprehensive unbiased proteomics study reported to date. This achievement has been uniquely enabled by the Proteograph XT Assay kit and the Orbitrap Astral mass spectrometer, demonstrating a new standard for proteomics discovery and translational research.
Seer, as a life sciences company, has developed transformative products that open a new gateway to the proteome. Their Proteograph Product Suite is an integrated solution designed for deep, unbiased proteomic analysis at scale, making it a valuable contribution to the field of life sciences and healthcare.
Similarly, PrognomiQ, a healthcare company founded in 2020, has played a crucial role in advancing multi-omics human tests for cancer and other complex diseases. Their use of leading-edge proteomics technologies, in addition to metabolomics and genomics technologies, reflects their commitment to improving human health through innovative and groundbreaking research.
The successful completion of this study represents a significant milestone in the field of cancer biomarker research, and it has the potential to bring about transformative changes in early cancer detection. The collaboration between Seer and Thermo Fisher, as well as the innovative approach taken by PrognomiQ, has paved the way for new standards in proteomic research and healthcare applications. This groundbreaking research has the potential to impact the lives of millions of individuals worldwide, and it represents a monumental achievement in the quest for early cancer detection.